|
Guler MN, Tscheiller NM, Sabater-Molina M, Gimeno JR, Nebigil CG. Evidence for reciprocal network interactions between injured hearts and cancer. Front Cardiovasc Med. 2022 Jul 15;9:929259. doi: 10.3389/fcvm.2022.929259. eCollection 2022. PubMed PMID: 35911555; PubMed Central PMCID: PMC9334681.
AÑO: 2022; IF: 3.6
|
35911555
|
Sabater Molina M, Gimeno Blanes JR. In recognition of the Spanish origin of CRISPR/Cas9. Implications for the treatment of familial heart disease. Rev Esp Cardiol (Engl Ed). 2024 Jul;77(7):597-598. doi: 10.1016/j.rec.2024.01.007. Epub 2024 Feb 19. No abstract available. English, Spanish. PubMed PMID: 38382800.
AÑO: 2024; IF: 4.9
|
|
Kaski JP, Norrish G, Gimeno Blanes JR, Charron P, Elliott P, Tavazzi L, Tendera M, Laroche C, Maggioni AP, Baban A, Khraiche D, Ziolkowska L, Limongelli G, Ojala T, Gorenflo M, Anastasakis A, Mostafa S, Caforio ALP; EORP Paediatric Cardiomyopathy Registry Investigators. Cardiomyopathies in children and adolescents: aetiology, management, and outcomes in the European Society of Cardiology EURObservational Research Programme Cardiomyopathy and Myocarditis Registry. Eur Heart J. 2024 Apr 21;45(16):1443-1454. doi: 10.1093/eurheartj/ehae109. PubMed PMID: 38427064; PubMed Central PMCID: PMC11448693.
AÑO: 2024; IF: 35.6
|
|
Bayonas-Ruiz A, Munoz-Franco FM, Sabater-Molina M, Martinez-Gonzalez-Moro I, Gimeno-Blanes JR, Bonacasa B. Concurrent Resistance and Cardiorespiratory Training in Patients with Hypertrophic Cardiomyopathy: A Pilot Study. J Clin Med. 2024 Apr 17;13(8):2324. doi: 10.3390/jcm13082324. PubMed PMID: 38673596; PubMed Central PMCID: PMC11050913.
AÑO: 2024; IF: 2.9
|
|
Martinez-Jimenez D, Hernandez Del Rincon JP, Sabater-Molina M, Perez-Martinez C, Torres C, Perez-Carceles MD, Luna A. Postmortem study of adrenomedullin and cortisol in femoral serum and pericardial fluid related to acute pulmonary edema. Int J Legal Med. 2025 Jan;139(1):353-359. doi: 10.1007/s00414-024-03337-6. Epub 2024 Sep 26. PubMed PMID: 39325159; PubMed Central PMCID: PMC11732926.
AÑO: 2025; IF: 2.3
|